| 211 | Humans |
| 112 | Coronavirus Infections (epidemiology) |
| 111 | Pneumonia, Viral (epidemiology) |
| 77 | Pneumonia, Viral (transmission) |
| 77 | Coronavirus Infections (transmission) |
| 53 | Disease Outbreaks |
| 53 | Betacoronavirus |
| 50 | Coronavirus Infections (diagnosis) |
| 50 | China (epidemiology) |
| 47 | Pneumonia, Viral (diagnosis) |
| 44 | Betacoronavirus (isolation & purification) |
| 43 | Coronavirus Infections (prevention & control) |
| 42 | China |
| 42 | Betacoronavirus (pathogenicity) |
| 41 | Pneumonia, Viral (prevention & control) |
| 36 | Betacoronavirus (genetics) |
| 34 | Pneumonia, Viral (complications) |
| 34 | Male |
| 34 | Coronavirus Infections (complications) |
| 32 | Female |
| 31 | Animals |
| 31 | Adult |
| 29 | Pneumonia, Viral (virology) |
| 29 | Coronavirus Infections (virology) |
| 27 | Travel |
| 26 | Middle Aged |
| 24 | Pandemics |
| 21 | Coronavirus Infections (therapy) |
| 20 | Pneumonia, Viral (therapy) |
| 18 | Phylogeny |
| 18 | Lung (diagnostic imaging) |
| 17 | Public Health |
| 17 | Pneumonia, Viral (drug therapy) |
| 15 | Pneumonia, Viral (diagnostic imaging) |
| 15 | Genome, Viral |
| 15 | Coronavirus Infections (drug therapy) |
| 15 | Antiviral Agents (therapeutic use) |
| 14 | Tomography, X-Ray Computed |
| 14 | Coronavirus Infections (diagnostic imaging) |
| 13 | Young Adult |
| 13 | Pneumonia, Viral (pathology) |
| 13 | Fever (etiology) |
| 13 | Disease Outbreaks (prevention & control) |
| 13 | Coronavirus Infections (pathology) |
| 13 | Aged |
| 12 | Pneumonia, Viral |
| 12 | Lung (pathology) |
| 12 | Coronavirus Infections |
| 12 | Child |
| 10 | Zoonoses |
| 10 | Risk Factors |
| 10 | Cough (etiology) |
| 10 | Chiroptera (virology) |
| 9 | Retrospective Studies |
| 9 | Pneumonia, Viral (etiology) |
| 8 | Severity of Illness Index |
| 8 | Radiography, Thoracic |
| 8 | Pneumonia, Viral (mortality) |
| 8 | Global Health |
| 8 | Epidemics |
| 8 | Coronavirus Infections (mortality) |
| 8 | Betacoronavirus (drug effects) |
| 7 | Real-Time Polymerase Chain Reaction |
| 7 | Infection Control |
| 7 | Europe (epidemiology) |
| 7 | Coronavirus |
| 7 | Betacoronavirus (physiology) |
| 7 | Adolescent |
| 6 | United States |
| 6 | SARS Virus (pathogenicity) |
| 6 | Patient Isolation |
| 6 | Models, Theoretical |
| 6 | Infant |
| 6 | Dyspnea (etiology) |
| 6 | Disease Progression |
| 6 | Communicable Diseases, Emerging (virology) |
| 5 | World Health Organization |
| 5 | United States (epidemiology) |
| 5 | SARS Virus (genetics) |
| 5 | Risk Assessment |
| 5 | Respiration, Artificial |
| 5 | Republic of Korea |
| 5 | Republic of Korea (epidemiology) |
| 5 | Quarantine |
| 5 | Population Surveillance |
| 5 | Pneumonia, Viral (psychology) |
| 5 | Health Personnel |
| 5 | Forecasting |
| 5 | Coronavirus Infections (veterinary) |
| 5 | Coronavirus Infections (psychology) |
| 5 | Communication |
| 5 | Communicable Diseases, Emerging (epidemiology) |
| 5 | Betacoronavirus (classification) |
| 5 | Amino Acid Sequence |
| 5 | Air Travel |
| 5 | Aged, 80 and over |
| 4 | Zoonoses (virology) |
| 4 | Zoonoses (transmission) |
| 4 | Travel Medicine |
| 4 | Severe Acute Respiratory Syndrome (virology) |
| 4 | Severe Acute Respiratory Syndrome (transmission) |
| 4 | Severe Acute Respiratory Syndrome (pathology) |
| 4 | Severe Acute Respiratory Syndrome (epidemiology) |
| 4 | SARS Virus |
| 4 | Ritonavir (therapeutic use) |
| 4 | RNA, Viral (genetics) |
| 4 | Practice Guidelines as Topic |
| 4 | Pneumonia, Viral (veterinary) |
| 4 | Pandemics (prevention & control) |
| 4 | Middle East Respiratory Syndrome Coronavirus (pathogenicity) |
| 4 | Lopinavir (therapeutic use) |
| 4 | Infectious Disease Transmission, Patient-to-Professional |
| 4 | Infectious Disease Incubation Period |
| 4 | Infant, Newborn |
| 4 | Drug Evaluation, Preclinical |
| 4 | Coronavirus (genetics) |
| 4 | Contact Tracing |
| 4 | Communicable Diseases, Emerging |
| 4 | Colorectal Neoplasms (complications) |
| 4 | Clinical Trials as Topic |
| 4 | Antiviral Agents (pharmacology) |
| 3 | Zoonoses (epidemiology) |
| 3 | World Health Organization (organization & administration) |
| 3 | Virus Replication |
| 3 | Viral Proteins (chemistry) |
| 3 | Universities |
| 3 | United Kingdom (epidemiology) |
| 3 | Time Factors |
| 3 | Spike Glycoprotein, Coronavirus (genetics) |
| 3 | Spike Glycoprotein, Coronavirus (chemistry) |
| 3 | Severe Acute Respiratory Syndrome (drug therapy) |
| 3 | Severe Acute Respiratory Syndrome (diagnostic imaging) |
| 3 | Sequence Alignment |
| 3 | Seasons |
| 3 | SARS Virus (drug effects) |
| 3 | Respiratory Distress Syndrome, Adult (virology) |
| 3 | Public Health Surveillance |
| 3 | Prognosis |
| 3 | Pneumonia, Viral (immunology) |
| 3 | Peptidyl-Dipeptidase A (metabolism) |
| 3 | Models, Genetic |
| 3 | Middle East Respiratory Syndrome Coronavirus |
| 3 | Middle East Respiratory Syndrome Coronavirus (drug effects) |
| 3 | Mental Health Services |
| 3 | Melia azedarach |
| 3 | Medical History Taking |
| 3 | Mass Screening |
| 3 | Mass Screening (methods) |
| 3 | Internationality |
| 3 | Information Dissemination |
| 3 | Infection Control (methods) |
| 3 | Incidence |
| 3 | Immunity |
| 3 | Hygiene |
| 3 | Host Specificity |
| 3 | Health Services Accessibility |
| 3 | Genome, Viral (genetics) |
| 3 | Fatigue (etiology) |
| 3 | Family Health |
| 3 | Emergencies |
| 3 | Drug Repositioning |
| 3 | Drug Discovery |
| 3 | Drug Design |
| 3 | Drug Combinations |
| 3 | Disease Transmission, Infectious |
| 3 | Disease Susceptibility |
| 3 | Disease Reservoirs (virology) |
| 3 | Disaster Planning |
| 3 | Diagnosis, Differential |
| 3 | Delivery of Health Care |
| 3 | Cross Infection (prevention & control) |
| 3 | Coronavirus Infections (immunology) |
| 3 | Coronavirus (pathogenicity) |
| 3 | Civil Defense |
| 3 | Child, Preschool |
| 3 | Biomedical Research |
| 3 | Betacoronavirus (metabolism) |
| 3 | Basic Reproduction Number |
| 3 | Asymptomatic Infections |
| 3 | Alanine (therapeutic use) |
| 3 | Alanine (analogs & derivatives) |
| 2 | virus |
| 2 | Whole Genome Sequencing |
| 2 | Vulnerable Populations |
| 2 | Virus |
| 2 | Virus Shedding |
| 2 | Virus Diseases (transmission) |
| 2 | Virus Diseases (epidemiology) |
| 2 | Viral Vaccines (therapeutic use) |
| 2 | Viral Vaccines (immunology) |
| 2 | Viral Proteins (genetics) |
| 2 | Viral Load |
| 2 | Vero Cells |
| 2 | Uncertainty |
| 2 | Thailand |
| 2 | Taiwan |
| 2 | Spike Glycoprotein, Coronavirus (metabolism) |
| 2 | Spike Glycoprotein, Coronavirus (immunology) |
| 2 | Social Media |
| 2 | Social Conditions |
| 2 | Singapore (epidemiology) |
| 2 | Ships |
| 2 | Sex Distribution |
| 2 | Severe Acute Respiratory Syndrome |
| 2 | Sequence Analysis, Protein |
| 2 | Science (organization & administration) |
| 2 | SARS Virus (immunology) |
| 2 | SARS Virus (classification) |
| 2 | Rural Population |
| 2 | Risk |
| 2 | Respiratory Tract Infections (epidemiology) |
| 2 | Respiratory Sounds |
| 2 | Respiratory Insufficiency |
| 2 | Respiratory Insufficiency (virology) |
| 2 | Respiratory Insufficiency (therapy) |
| 2 | Respiratory Distress Syndrome, Adult (therapy) |
| 2 | Research |
| 2 | Recombinant Proteins (therapeutic use) |
| 2 | Racism |
| 2 | Public Health Practice |
| 2 | Prevalence |
| 2 | Predictive Value of Tests |
| 2 | Population Surveillance (methods) |
| 2 | Pneumonia, Viral (metabolism) |
| 2 | Pharynx (virology) |
| 2 | Personal Protective Equipment |
| 2 | Periodicals as Topic |
| 2 | Peptidyl-Dipeptidase A (physiology) |
| 2 | Patient Safety |
| 2 | Patient Education as Topic |
| 2 | Patient Discharge |
| 2 | Oligodendrocyte |
| 2 | Occupational Exposure |
| 2 | Nucleosides (therapeutic use) |
| 2 | Nucleic Acid Amplification Techniques |
| 2 | Noninvasive Ventilation |
| 2 | Mutation Rate |
| 2 | Mortality (trends) |
| 2 | Models, Statistical |
| 2 | Models, Molecular |
| 2 | Middle East Respiratory Syndrome Coronavirus (genetics) |
| 2 | Microbial Viability |
| 2 | Mental Health |
| 2 | Masks |
| 2 | Macau (epidemiology) |
| 2 | Leukocyte Count |
| 2 | Latin America (epidemiology) |
| 2 | Japan (epidemiology) |
| 2 | International Cooperation |
| 2 | Intensive Care Units |
| 2 | Intensive Care Units, Neonatal |
| 2 | Inpatients |
| 2 | Host-Pathogen Interactions |
| 2 | Hospitals |
| 2 | Hospitals, Psychiatric |
| 2 | Hospitalization |
| 2 | Health Workforce |
| 2 | Health Policy |
| 2 | Health Personnel (psychology) |
| 2 | Guidelines as Topic |
| 2 | Germany |
| 2 | Genetic Variation |
| 2 | Feces (virology) |
| 2 | Evolution, Molecular |
| 2 | Evidence-Based Medicine |
| 2 | Epidemiological Monitoring |
| 2 | Emigration and Immigration |
| 2 | Drugs, Chinese Herbal |
| 2 | Drugs, Chinese Herbal (therapeutic use) |
| 2 | Disease Reservoirs |
| 2 | Disease Reservoirs (veterinary) |
| 2 | Disease Outbreaks (statistics & numerical data) |
| 2 | Decision Making |
| 2 | Databases, Genetic |
| 2 | Critical Illness |
| 2 | Critical Illness (therapy) |
| 2 | Critical Care |
| 2 | Critical Care (standards) |
| 2 | Coronavirus Infections (metabolism) |
| 2 | Coronavirus (isolation & purification) |
| 2 | Consensus |
| 2 | Comorbidity |
| 2 | Communicable Disease Control |
| 2 | Communicable Disease Control (methods) |
| 2 | Colorectal Neoplasms (therapy) |
| 2 | Cluster Analysis |
| 2 | Chlorocebus aethiops |
| 2 | Chiroptera |
| 2 | Cell Line |
| 2 | Brazil |
| 2 | Blood Chemical Analysis |
| 2 | Biomedical Research (trends) |
| 2 | Biomarkers (blood) |
| 2 | Betacoronavirus (immunology) |
| 2 | Betacoronavirus (chemistry) |
| 2 | Base Sequence |
| 2 | Australia (epidemiology) |
| 2 | Asymptomatic Diseases |
| 2 | Anxiety |
| 2 | Antiviral Agents (supply & distribution) |
| 2 | Antiviral Agents (chemistry) |
| 2 | Antibodies, Viral (immunology) |
| 2 | Antibodies, Monoclonal (therapeutic use) |
| 2 | Age Factors |
| 2 | Age Distribution |
| 2 | Adrenal Cortex Hormones (therapeutic use) |
| 2 | Adenosine Monophosphate (therapeutic use) |
| 2 | Adenosine Monophosphate (analogs & derivatives) |
| 2 | Adaptation, Psychological |
| 2 | Access to Information |
| 1 | xylometazoline |
| 1 | viral escape |
| 1 | therapeutic proteins |
| 1 | tandem repeats |
| 1 | sponge medicine |
| 1 | secretory diarrhea |
| 1 | secondary metabolites |
| 1 | protein synthesis |
| 1 | prion |
| 1 | plantibodies |
| 1 | pharmacokinetics |
| 1 | neurodegenerative diseases |
| 1 | nervous system |
| 1 | natural product |
| 1 | nasal spray |
| 1 | motor neuron disease |
| 1 | molecular farming |
| 1 | migrating action potential complexes |
| 1 | membranes |
| 1 | lipids |
| 1 | licorice root |
| 1 | intestinal electromyography |
| 1 | inflammation |
| 1 | immunologic tolerance |
| 1 | glycyrrhizic acid |
| 1 | glutamate |
| 1 | genetic association |
| 1 | gene therapy |
| 1 | gene polymorphism |
| 1 | excitotoxic amino acids |
| 1 | edible vaccines |
| 1 | drug interaction |
| 1 | cytoskeleton |
| 1 | cancer |
| 1 | calcium |
| 1 | biologically active nutrient additives |
| 1 | antiviral |
| 1 | antiviral drugs |
| 1 | antiviral activity |
| 1 | Zoonoses (diagnosis) |
| 1 | Zika Virus |
| 1 | Zika Virus Infection (transmission) |
| 1 | Xenophobia (prevention & control) |
| 1 | Xenogarft |
| 1 | Writing |
| 1 | Weight gain |
| 1 | Web Browser (trends) |
| 1 | Web Browser (statistics & numerical data) |
| 1 | Weather |
| 1 | Waste Management (methods) |
| 1 | Virus Physiological Phenomena |
| 1 | Virus Diseases (virology) |
| 1 | Virus Diseases (drug therapy) |
| 1 | Virus Attachment |
| 1 | Virus Attachment (drug effects) |
| 1 | Virulence |
| 1 | Virtual hits |
| 1 | Virology (trends) |
| 1 | Virological diagnosis |
| 1 | Viral infectivity |
| 1 | Viral enteritis |
| 1 | Viral diarrhea |
| 1 | Viral Vaccines |
| 1 | Viral Vaccines (supply & distribution) |
| 1 | Viral Vaccines (adverse effects) |
| 1 | Viral Tropism |
| 1 | Viral Structural Proteins (physiology) |
| 1 | Viral Proteins |
| 1 | Viral Nonstructural Proteins |
| 1 | Viral Nonstructural Proteins (physiology) |
| 1 | Vaccine |
| 1 | Vaccination |
| 1 | United Kingdom |
| 1 | Triage |
| 1 | Treatment Outcome |
| 1 | Travel (statistics & numerical data) |
| 1 | Travel (legislation & jurisprudence) |
| 1 | Travel (economics) |
| 1 | Transportation |
| 1 | Transportation (statistics & numerical data) |
| 1 | Transmissible gastroenteritis coronavirus |
| 1 | Transient paralysis |
| 1 | Tissue banking |
| 1 | Thrombopoietin |
| 1 | Throat swab |
| 1 | Thiosemicarbazones |
| 1 | Therapy |
| 1 | Teaching |
| 1 | Switzerland (epidemiology) |
| 1 | Survival rate |
| 1 | Surveys and Questionnaires |
| 1 | Students (psychology) |
| 1 | Stress, Psychological |
| 1 | State Medicine (organization & administration) |
| 1 | Spray-dried |
| 1 | Spouses |
| 1 | Spongy degeneration |
| 1 | Spinal cord |
| 1 | Spike Glycoprotein, Coronavirus |
| 1 | Spike Glycoprotein, Coronavirus (drug effects) |
| 1 | Sore throat |
| 1 | Solubility |
| 1 | Societies, Medical |
| 1 | Social Support |
| 1 | Social Stigma |
| 1 | Social Media (trends) |
| 1 | Social Media (statistics & numerical data) |
| 1 | Social Isolation |
| 1 | Social Distance |
| 1 | Social Discrimination |
| 1 | Social Capital |
| 1 | Snakes (virology) |
| 1 | Snakes (genetics) |
| 1 | Small Molecule Libraries (therapeutic use) |
| 1 | Small Molecule Libraries (pharmacology) |
| 1 | Sleep Wake Disorders (epidemiology) |
| 1 | Sleep (physiology) |
| 1 | Sino-Germany Science Center |
| 1 | Sincalide |
| 1 | Signal transduction |
| 1 | Sign Language |
| 1 | Sialic acid |
| 1 | Severe Acute Respiratory Syndrome (therapy) |
| 1 | Severe Acute Respiratory Syndrome (prevention & control) |
| 1 | Severe Acute Respiratory Syndrome (etiology) |
| 1 | Severe Acute Respiratory Syndrome (diagnosis) |
| 1 | Severe Acute Respiratory Syndrome (complications) |
| 1 | Serum Albumin |
| 1 | Sequence Homology, Nucleic Acid |
| 1 | Sequence Analysis, DNA |
| 1 | Sensitivity and Specificity |
| 1 | Semliki Forest virus |
| 1 | Self-assembly |
| 1 | Security Measures |
| 1 | Search Engine (statistics & numerical data) |
| 1 | Science (standards) |
| 1 | Science (economics) |
| 1 | Schwann cell |
| 1 | Schools |
| 1 | Saudi Arabia (epidemiology) |
| 1 | Salmonella |
| 1 | SARS Virus (physiology) |
| 1 | SARS Virus (chemistry) |
| 1 | Rotavirus |
| 1 | Risk Management |
| 1 | Ribonucleotides (therapeutic use) |
| 1 | Rhinitis |
| 1 | Reverse Transcriptase Polymerase Chain Reaction |
| 1 | Respiratory Tract Infections |
| 1 | Respiratory Tract Infections (virology) |
| 1 | Respiratory Tract Infections (drug therapy) |
| 1 | Respiratory Tract Infections (complications) |
| 1 | Respiratory System (physiopathology) |
| 1 | Respiratory Mechanics |
| 1 | Respiratory Distress Syndrome, Adult (etiology) |
| 1 | Respiration, Artificial (adverse effects) |
| 1 | Research Personnel (supply & distribution) |
| 1 | Research Personnel (standards) |
| 1 | Research Personnel (legislation & jurisprudence) |
| 1 | Research (trends) |
| 1 | Research (standards) |
| 1 | Reproducibility of Results |
| 1 | Remyelination |
| 1 | Rehabilitation (methods) |
| 1 | Recursive partitioning |
| 1 | Recombination, Genetic |
| 1 | Recombination, Genetic (genetics) |
| 1 | Recombinant Proteins (pharmacology) |
| 1 | Receptors, Virus |
| 1 | Receptors, Virus (metabolism) |
| 1 | Receptors, Virus (chemistry) |
| 1 | Receptors, Virus (biosynthesis) |
| 1 | Receptors, Virus (antagonists & inhibitors) |
| 1 | Receptors, Interleukin-2 (metabolism) |
| 1 | Receptor |
| 1 | Receptor, Angiotensin, Type 2 (biosynthesis) |
| 1 | Reactive thrombocytosis |
| 1 | Radiologists |
| 1 | Radiography |
| 1 | ROC Curve |
| 1 | RNA, Viral (blood) |
| 1 | RNA, Viral (analysis) |
| 1 | RNA interference (RNAi) |
| 1 | RNA Replicase (metabolism) |
| 1 | RNA Replicase (genetics) |
| 1 | RNA Replicase (chemistry) |
| 1 | Questionnaires |
| 1 | Quarantine (standards) |
| 1 | Quarantine (methods) |
| 1 | Qualitative Research |
